Arcus Biosciences appoints Dr David Lacey to its Board of Directors

– USA, CA –  Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that David Lacey, M.D. has joined its Board of Directors.

Dr. Lacey has had a distinguished academic and highly accomplished biopharmaceutical industry career discovering and creating life-changing and critical quality of life improvement therapies for patients.

“Over the years, I have had the privilege of working closely with David in multiple capacities,” said Terry Rosen, Ph.D., CEO.

He added: “From our early days as collaborators when I was at Tularik and as long-term colleagues at Amgen, I realized that David personifies what drives the biotechnology industry—he is highly innovative, is able to recognize extraordinary opportunities and has humanity and empathy that are always patient-focused. His wealth of scientific, leadership and life experiences provide him with unique knowledge and wisdom that will be invaluable to Arcus as it moves towards late-stage development and commercialization but retains an emphasis on a breakthrough discovery. David’s advice and perspectives were central in the formation and success of Flexus and the subsequent founding of Arcus, and his involvement with the Arcus team since our inception as a member of our Scientific Advisory Board positions him to genuinely impact the strategic decisions and direction of the Company to ultimately provide benefit to patients.”

About Dr David Lacey

During his 17-year tenure at Amgen, Dr. Lacey oversaw Amgen’s Discovery Research organization during a key period in the company’s history, leading more than 1,200 scientists across a portfolio of drug discovery and development projects in the therapeutic areas of hematology/oncology, inflammation, metabolic disorders, and neuroscience. At Amgen, Dr. Lacey helped make significant advancements in the understanding of bone biology, playing a fundamental role in the discovery of osteoprotegerin and in the understanding of the RANK/RANK ligand pathway in bone metabolism that paved the way for the development of Prolia for osteoporosis and XGEVA for cancer-­related bone diseases, which had combined annual sales of more than $2 billion. Denosumab has received a number of awards including the US 2011 Prix Galien award for best new biotechnology product. Dr. Lacey also initiated the clinical studies of keratinocyte growth factor, which ultimately was approved as Kepivance for chemotherapy patients with severe oral mucositis. Prior to joining Amgen, Dr. Lacey was on the faculty at Washington University Medical Center in St. Louis, Missouri where he taught pathology residents and medical students, performed professional medical service in anatomic pathology, and pursued NIH-funded research in bone cell biology.

“It has been quite motivating to advise a company that so highly values a long-term commitment to and investment in pioneering drug discovery and development and fully leveraging the potential of its clinical portfolio for the treatment of cancer,” said Dr. Lacey. “Arcus has created a world-class R&D engine, underpinned by a team of successful industry veterans, and I am excited to be a part of this team as it continues to move toward its vision of delivering a sustainable pipeline of therapies that provide transformational therapeutic benefit.”

Dr. Lacey received his bachelor’s degree in biology and his M.D. degree from the University of Colorado where he served as Chief Resident of Anatomic Pathology in his final year of training. He is board-certified in anatomical pathology. Dr. Lacey currently serves as a Board member for several biotech companies and acts as an esteemed advisor to a number of academic institutions, biotechnology companies, and venture capital firms.

About Arcus Biosciences

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. AB928, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic, is being evaluated in several Phase 1b/2 studies across multiple indications, including prostate, colorectal, non-small cell lung, pancreatic, triple-negative breast and renal cell cancers. AB680, the first small-molecule CD73 inhibitor in the clinic, is in Phase 1 development for first-line treatment of metastatic pancreatic cancer. AB154, an anti-TIGIT monoclonal antibody, is in Phase 2 development for first-line treatment of metastatic non-small cell lung cancer in combination with zimberelimab and AB928. Zimberelimab (AB122), Arcus’s anti-PD1 monoclonal antibody, is being evaluated in a Phase 1b study as monotherapy for cancers with no approved anti-PD1 treatment options, as well as in combinations across the portfolio.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.